


## PHARMACEUTICAL 2019



## Mirati Therapeutics Inc. Rank 176 of 371





## PHARMACEUTICAL 2019



## Mirati Therapeutics Inc. Rank 176 of 371

The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 242% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -139%, being 192% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	226,660
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,146
Liabilities, Non-Current	0
Other Assets	1,321
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	732
Other Net Income	4,209
Property and Equipment	473
Research and Development	93,872
Revenues	12,926
Selling, General and Administrative Expense	21,681

Output Variable	Value in 1000 USD
Assets	228,454
Liabilities	26,878
Expenses	115,553
Stockholders Equity	201,576
Net Income	-98,418
Comprehensive Net Income	-98,418
Economic Capital Ratio	-139%